[ 18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: Influence of antiandrogen therapy - A preliminary study

Nuclear Medicine Communications

Volumn 33, Issue 8, 2012, Pages 889-894

  Henninger, Benjamin ^a   Vesco, Peter ^a   Putzer, Daniel ^a   Kendler, Dorota ^a   Loizides, Alexander ^a   Bale, Reto J ^a   Virgolini, Irene J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

1818F choline; antiandrogen therapy; biochemical recurrence; positron emission tomography; prostate cancer

Indexed keywords

ANTIANDROGEN; CHOLINE; FLUORINE 18; PROSTATE SPECIFIC ANTIGEN; DIAGNOSTIC AGENT; FLUORINE;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FOLLOW UP; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; PROSTATECTOMY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHOLINE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84863475856     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328355990f     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. See WA, Tyrrell CJ. The addition of bicalutamide 150mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006; 132 (Suppl 1):S7-S16.
3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169:517-523.
4. Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: Results of the SEARCH database. Urology 2003; 61:736-741.
5. Hellstrom M, Haggman M, Brandstedt S, De la Torre M, Pedersen K, Jarlsfeldt I, et al. Histopathological changes in androgen-deprived localized prostatic cancer. A study in total prostatectomy specimens. Eur Urol 1993; 24:461-465.
6. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology 2001; 218:365-374.
7. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-995.
8. DeGrado TR, Coleman RE,Wang S, Baldwin SW, Orr MD, Robertson CN, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 2001; 61:110-117.
9. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43:187-199.
10. DeGrado TR, Baldwin SW,Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805-1814.
11. Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L. Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence Synthesizer. Nucl Med Biol 2008; 35:255-260.
12. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA <5 ng/ml Mol. Imaging Biol. 2006 8 43-48
13. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTATyr3- octreotide PET in comparison to CTand bone scintigraphy. J Nucl Med 2009; 50:1214-1221.
14. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 2007; 37:420-428.
15. Schillaci O, Calabria F, Tavolozza M, Ciccio C, Carlani M, Caracciolo CR, et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: Experience in 80 patients with prostate cancer. Nucl Med Commun 2010; 31:39-45.
16. Schmid DT, John H, Zweifel R, Cservenyak T,Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: Initial experience. Radiology 2005; 235:623-628.
17. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007; 51:1175-1184.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
19. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37:301-309.
20. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:253-263.
21. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44:32-38, discussion 8-9.
22. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18-23.
23. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et al. 18F-choline and/or 11C-Acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostate-specific antigen values (< 1 ng/mL) after radical prostatectomy BJU Int 2007 99 1415-1420
24. Coleman R, DeGrado T, Wang S, Baldwin S, Orr M, Reiman R, et al. 9:30-9:45. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000; 3:147.
25. Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C]acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006; 33:977-984.
26. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273-280.
27. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: Relation to PSA levels, tumour stage and anti-Androgenic therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1065-1073.
28. Garcia JR, Soler M, Blanch MA, Ramirez I, Riera E, Lozano P, et al. PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer. Rev Esp Med Nucl 2009; 28: 95-100.
29. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33:1387-1398.